Key clinical point: When compared with conventional immunosuppression, posttransplant cyclophosphamide can reduce graft-versus-host disease without affecting relapse.
Major finding: The graft-versus-host disease–free and relapse-free survival at 12 months was 22% in the conventional immunosuppression arm and 45% in the posttransplant cyclophosphamide arm (P = .001).
Study details: A phase 3 trial of 160 patients with hematologic malignancies undergoing allogeneic transplant.
Disclosures: The study was funded by the Dutch Cancer Society, and Novartis provided the mycophenolic acid used in the study. Dr. Broers reported having no conflicts of interest.
Broers AEC et al. ASH 2019, Abstract 1.